Search
Make Good Use of Your Sidebar

Use this space for anything from simple blocks of text to powerful widgets, like our Twitter and Flickr widgets. Learn more.

To access Website Management, hit the 'esc' key or use this Login link.

Blog Index
The journal that this archive was targeting has been deleted. Please update your configuration.
Navigation

Photoimmunotherapy Therapy 

A new antibody conjugate system that enables highly specific cancer cell killing by direct contact to the cell surface and laser-mediated activation at the tumor site

Photoimmunotherapy was developed by Dr. H. Kobayashi and Dr. P. L. Choyke, the scientific heads of the Molecular Imaging Program at the National Cancer Institute (NCI) and described in Nature Medicine (1).  

  1. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Nat Med. 2011 Nov 6; 17 (12): 1685-91.

Video Describing the Technology

 

Photoimmunotherapy (PIT) is based on three components:

  1. An antibody that binds cancer surface antigens for tumor selective targeting.
  2. The IRDye700DX molecule is conjugated to the antibody with stable linkers.
  3. Laser-activation of the antibody conjugate bound to the cancer cells induces specific and rapid killing of only cancer cells sparing dabame to sorrounding tissue.

The combination of cancer targeting with antibody binding to surface antigens and localized laser actyivation of the conjugate permits highly effective cancer ablation while preserving organ function.

VIDEO: Real-time observation of Tra-IR700 mediated phototoxic cell death after cell surface binding.

VIDEO: Real-time observation of Tra-IR700 mediated phototoxic cell death after receptor internalization.

VIDEO: Target specific phototoxicity in response to Tra-IR700 mediated photoimmunotherapy in vitro.